<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494687</url>
  </required_header>
  <id_info>
    <org_study_id>EP2014022</org_study_id>
    <nct_id>NCT02494687</nct_id>
  </id_info>
  <brief_title>Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy</brief_title>
  <official_title>Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Regional Medical Center</source>
  <brief_summary>
    <textblock>
      Gastroparesis is a digestive disorder in which motility of the stomach is either slowed or&#xD;
      absent. The gastroparesis prevents normal digestion from occurring. The purpose of this study&#xD;
      is to provide oral Domperidone offered under the U.S. Food and Drug Administration (FDA)&#xD;
      expanded access program, to patients that, based on the treating doctor's assessment, could&#xD;
      benefit from , a prokinetic effect for the relief of refractory gastroesophageal reflux&#xD;
      disease with upper gastrointestinal (GI) symptoms, gastroparesis, and chronic constipation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the discretion of the Investigator, 10-30 mg of oral domperidone is administered QID (four&#xD;
      times a day). The Investigator will be starting patients on 10 mg four times a day for 2&#xD;
      weeks, then increase to 20 mg four times a day for 2 weeks. The participant will be evaluated&#xD;
      at each time point. If the participant still is not having relief of symptoms the&#xD;
      investigator may increase their dose to 30mg four times a day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Oncology Patients With Gastroparesis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Domperidone</intervention_name>
    <description>10 mg of oral domperidone administered (four times a day) for two weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Domperidone</intervention_name>
    <description>Increased to 20 mg four times a day for 2 weeks at the Investigator's discretion</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Domperidone</intervention_name>
    <description>Increased to 30 mg four times a day at the Investigator's discretion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female&#xD;
&#xD;
          2. Age 18 and older&#xD;
&#xD;
          3. Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn,&#xD;
             upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility&#xD;
             disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation&#xD;
             refractory to standard therapy.&#xD;
&#xD;
          4. Patients must have a comprehensive evaluation (physical exam and also may include EGD,&#xD;
             gastric emptying study, as clinically necessary) to eliminate other causes of their&#xD;
             symptoms.&#xD;
&#xD;
          5. Patient has signed informed consent for the administration of domperidone that informs&#xD;
             the patient of potential adverse events including:&#xD;
&#xD;
               -  increased prolactin levels&#xD;
&#xD;
               -  extrapyramidal side-effects&#xD;
&#xD;
               -  breast changes&#xD;
&#xD;
               -  cardiac arrhythmias including QT prolongation and death&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        History of, or current, arrhythmias including ventricular tachycardia, ventricular&#xD;
        fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not&#xD;
        necessarily excluded.&#xD;
&#xD;
          1. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged&#xD;
             QTc (QTc&gt; 450 milliseconds for males, QTc&gt;470 milliseconds for females).&#xD;
&#xD;
          2. Clinically significant electrolyte disorders.&#xD;
&#xD;
          3. Gastrointestinal hemorrhage or obstruction&#xD;
&#xD;
          4. Presence of a prolactinoma (prolactin-releasing pituitary tumor).&#xD;
&#xD;
          5. Pregnant or breast feeding female&#xD;
&#xD;
          6. Known allergy to domperidone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Raman Battish, MD</last_name>
    <phone>215-537-7400</phone>
    <email>Raman.Battish@ctca-hope.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jack Medendorp</last_name>
    <phone>215-537-3160</phone>
    <email>Jack.Medendorp@ctca-hope.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastern Regional Medical Center, Inc.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Raman Battish, MD</last_name>
      <phone>215-537-7400</phone>
      <email>Raman.Battish@ctca-hope.com</email>
    </contact>
    <contact_backup>
      <last_name>Jack Medendorp</last_name>
      <phone>215-537-3160</phone>
      <email>Jack.Medendorp@ctca-hope.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

